Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1012428 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Andreas Soerensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre and Department of Immunology and Microbiology, Faculty of Health…. Hauptthemen laut MEDLINE: Hepacivirus, Viral Envelope Proteins, Hepatitis C Antibodies, Antibodies, Neutralizing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Lundbeck Foundation, Novo Nordisk Fonden.
Abstract (Originalsprache)
Identification and characterization of antibody epitope targets on the hepatitis C virus (HCV) envelope proteins remain crucial for developing an effective vaccine. Building on prior research defining E1/E2 antibody epitope clustering, we screened a phage display library derived from a chronic HCV patient against detergent-extracted full-length E1/E2 from both the patient’s acute-phase isolate (H77, genotype 1a) and a heterologous isolate (S52, genotype 3a). This approach yielded a panel of V H 1-69 derived antibody fragments (Fabs) with similar characteristics. Interestingly, all members of the panel exhibited blocking activity against both antigenic region 2 and 3 (AR2 and AR3) in competition ELISAs, which contrasts with the behavior of most previously identified AR3-targeting antibodies. The V H 1-69 derived binders had a high affinity for soluble E2 in both Fab and IgG formats, with dissociation constants in the low picomolar range. These Fab binders were broadly neutralizing against a panel of HCV cell culture viruses of genotype 1-6 with higher potency than the well-characterized reference Fab, AR3A. However, in the IgG format the antibodies had similar potency. These findings expand our understanding of potential targets for vaccine development by characterizing a panel of antibodies targeting an AR3 epitope also involving or occluding the back layer of E2. The broad neutralization and high affinity of these antibodies suggest a benefit to targeting both the back layer and the front layer of E2 in HCV vaccine designs to expand the repertoire of broadly neutralizing antibodies, thereby offering promise for the development of more effective preventive measures against this pervasive human pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, Copenhagen University Hospital, University of C…
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
- Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
- Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Jannick Prentoe
Förderung
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Lundbeck Foundation
- Novo Nordisk Fonden
- Danmarks Frie Forskningsfond
- Candys Foundation
- Mauritzen La Fontaine Foundation
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Soerensen, A., Popovic, F., Olesen, C. H., Mendez, B. L., Lohse, B., Chen, Z., Farci, P., Purcell, R. H., Alter, H. J., Barfod, L. K., Bukh, J., & Prentoe, J. (2025). Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012428
Vancouver
Soerensen A, Popovic F, Olesen CH, Mendez BL, Lohse B, Chen Z, et al. Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012428
BibTeX
@article{Soerensen2025,
author = {Soerensen, Andreas and Popovic, Filip and Olesen, Christina Holmboe and Mendez, Blanca Lopez and Lohse, Brian and Chen, Zhaochun and Farci, Patrizia and Purcell, Robert H and Alter, Harvey J and Barfod, Lea Klingenberg and Bukh, Jens and Prentoe, Jannick},
title = {Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1012428}
}
EUVIMED